Telomere length correlates with disease severity and inflammation in sickle cell disease

Revista Brasileira de Hematologia e Hemoterapia

Volumn 39, Issue 2, 2017, Pages 140-145

  Colella, Marina Pereira ^a   Santana, Barbara A ^b,c   Conran, Nicola ^a   Tomazini, Vinicius ^a   Costa, Fernando F ^a   Calado, Rodrigo T ^b,c   Saad, Sara T Olalla ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP   (Brazil)

Author keywords

Inflammation; Sickle cell disease; Telomere length

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ACUTE CHEST SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMOLYTIC ANEMIA; HOSPITALIZATION; HUMAN; INFLAMMATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SOUTHERN BLOTTING; TELOMERE LENGTH;

EID: 85016818422     PISSN: 15168484     EISSN: 18060870     Source Type: Journal    
DOI: 10.1016/j.bjhh.2017.02.007     Document Type: Article

References (22)

1. Colella, M.P., De Paula, E.V., Conran, N., Machado-Neto, J.A., Annicchino-Bizzacchi, J.M., Costa, F.F., et al. Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. J Thromb Haemost 10:9 (2012), 1967–1970.
2. Almeida, C.B., Souza, L.E., Leonardo, F.C., Costa, F.T., Werneck, C.C., Covas, D.T., et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood 126:6 (2015), 711–720.
3. Conran, N., Franco-Penteado, C.F., Costa, F.F., Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 33:1 (2009), 1–16.
4. Dutra, F.F., Bozza, M.T., Heme on innate immunity and inflammation. Front Pharmacol, 5, 2014, 115.
5. Figueiredo, R.T., Fernandez, P.L., Mourao-Sa, D.S., Porto, B.N., Dutra, F.F., Alves, L.S., et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem 282:28 (2007), 20221–20229.
6. Blackburn, E.H., Switching and signaling at the telomere. Cell 106:6 (2001), 661–673.
7. Calado, R.T., Young, N.S., Telomere diseases. N Engl J Med 361:24 (2009), 2353–2365.
8. Masi, S., Salpea, K.D., Li, K., Parkar, M., Nibali, L., Donos, N., et al. Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med 50:6 (2011), 730–735.
9. Wolkowitz, O.M., Mellon, S.H., Epel, E.S., Lin, J., Dhabhar, F.S., Su, Y., et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress – preliminary findings. Kiechl S, editor. PLoS One, 6(3), 2011, e17837.
10. Gutierrez-Rodrigues, F., Santana-Lemos, B.A., Scheucher, P.S., Alves-Paiva, R.M., Calado, R.T., Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One, 9(11), 2014, e113747.
11. Cawthon, R.M., Telomere measurement by quantitative PCR. Nucleic Acids Res, 30(10), 2002, e47.
12. Brouilette, S.W., Moore, J.S., McMahon, A.D., Thompson, J.R., Ford, I., Shepherd, J., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case–control study. Lancet 369:9556 (2007), 107–114.
13. Calado, R.T., Cooper, J.N., Padilla-Nash, H.M., Sloand, E.M., Wu, C.O., Scheinberg, P., et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia 26:4 (2012), 700–707.
14. Drašar, E.R., Jiang, J., Gardner, K., Howard, J., Vulliamy, T., Vasavda, N., et al. Leucocyte telomere length in patients with sickle cell disease. Br J Haematol 165:5 (2014), 725–727.
15. Okpala, I., The intriguing contribution of white blood cells to sickle cell disease – a red cell disorder. Blood Rev 18:1 (2004), 65–73.
16. Litos, M., Sarris, I., Bewley, S., Seed, P., Okpala, I., Oteng-Ntim, E., White blood cell count as a predictor of the severity of sickle cell disease during pregnancy. Eur J Obstet Gynecol Reprod Biol 133:2 (2007), 169–172.
17. Kinney, T.R., Sleeper, L.A., Wang, W.C., Zimmerman, R.A., Pegelow, C.H., Ohene-Frempong, K., et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103:3 (1999), 640–645.
18. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:23 (1994), 1639–1644.
19. Opdenakker, G., Fibbe, W.E., Van Damme, J., The molecular basis of leukocytosis. Immunol Today 19:4 (1998), 182–189.
20. Conran, N., Saad, S.T., Costa, F.F., Ikuta, T., Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. Ann Hematol 86:4 (2007), 255–261.
21. Almeida, C.B., Favero, M.E., Pereira-Cunha, F.G., Lorand-Metze, I., Saad, S.T., Costa, F.F., et al. Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Exp Biol Med (Maywood) 236:11 (2011), 1239–1246.
22. Djaldetti, M., Bergman, M., Salman, H., Cohen, A.M., Fibach, E., Bessler, H., On the mechanism of post-splenectomy leukocytosis in mice. Eur J Clin Invest 33:9 (2003), 811–817.